Timor-Leste

Population 2018: 1.3 million

<table>
<thead>
<tr>
<th>Estimates of TB burden*, 2018</th>
<th>Number (thousands)</th>
<th>Rate (per 100 000 population)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total TB incidence</td>
<td>6.3 (4.1–9)</td>
<td>498 (322–711)</td>
</tr>
<tr>
<td>HIV-positive TB incidence</td>
<td>0.077 (0.044–0.12)</td>
<td>6.1 (3.5–9.5)</td>
</tr>
<tr>
<td>MDR/RR-TB incidence**</td>
<td>0.24 (0.082–0.48)</td>
<td>19 (6.4–38)</td>
</tr>
<tr>
<td>HIV-negative TB mortality</td>
<td>1.2 (0.71–1.8)</td>
<td>94 (56–142)</td>
</tr>
<tr>
<td>HIV-positive TB mortality</td>
<td>&lt;0.01 (0–0.025)</td>
<td>0.39 (0–2)</td>
</tr>
</tbody>
</table>

---

**Estimated proportion of TB cases with MDR/RR-TB, 2018**

- New cases: 3.1% (1.1–6.1)
- Previously treated cases: 15% (7.8–23)

---

**TB case notifications, 2018**

- Total new and relapse: 3,782
  - % tested with rapid diagnostics at time of diagnosis: 1%
  - % with known HIV status: 77%
  - % pulmonary: 83%
  - % bacteriologically confirmed**: 55%
  - % children aged 0-14 years: 8%
  - % women: 39%
  - % men: 53%

---

**Universal health coverage and social protection**

- TB treatment coverage (notified/estimated incidence), 2018: 60% (42–93)
- TB patients facing catastrophic total costs, 2017: 83% (80–96)
- TB case fatality ratio (estimated mortality/estimated incidence), 2018: 20% (10–32)

---

**TB/HIV care in new and relapse TB patients, 2018**

- Number (%)
  - Patients with known HIV status who are HIV-positive: 37 1%
    - on antiretroviral therapy: 37 100%

---

**Drug-resistant TB care, 2018**

- % of bacteriologically confirmed TB cases tested for rifampicin resistance **
  - New cases
  - Previously treated cases

---

**Laboratory-confirmed cases**

- MDR/RR-TB: 12, XDR-TB: 0

---

**Patients started on treatment**

- MDR/RR-TB: 12, XDR-TB: 0

---

**MDR-TB cases tested for resistance to second-line drugs**

- 0

---

**Treatment success rate and cohort size**

- New and relapse cases registered in 2017: 88% 3,470
- Previously treated cases, excluding relapse, registered in 2017: 92% 109
- HIV-positive TB cases registered in 2017: 26% 25
- MDR/RR-TB cases started on second-line treatment in 2016: 83% 6
- XDR-TB cases started on second-line treatment in 2016: 0

---

**TB preventive treatment, 2018**

- % of HIV-positive people (newly enrolled in care) on preventive treatment: 99% (91–100)
- % of children (aged < 5) household contacts of bacteriologically-confirmed TB cases on preventive treatment: 99% (91–100)

---

**TB financing, 2019**

- National TB budget (US$ millions): 3.2

---

* Ranges represent uncertainty intervals
** MDR is TB resistant to rifampicin and isoniazid; RR is TB resistant to rifampicin
*** Calculated for pulmonary cases only
* Includes cases with unknown previous TB treatment history
** Includes patients diagnosed before 2018 and patients who were not laboratory-confirmed